Cancer Metastases from Lung Adenocarcinoma Disappeared After Molecular Targeted Therapy: A Successfully Clinical Treatment Experience

Abstract

Introduction Molecular targeted therapy has shown certain therapeutic effects on various cancer types, especially lung cancer. Here, we report a case of a patient with unresectable non-small cell lung cancer (NSCLC) with bone metastases and metastatic lesions that disappeared after molecular targeted therapy. Patient Information A 49-year-old male patient’s chest CT scan showed a patchy, slightly high-density shadow on the upper lobe of the left lung with an unclear boundary. The multiple thoracic vertebrae, 4th lumbar vertebrae, multiple ribs, right sacroiliac joint, right hip joint, right inferior ramus of pubis, left middle and upper femur, and right proximal radial bone showed nodular and slightly high-density shadows. Interventions The patient was not considered eligible for tumor resection due to his metastatic lesions. A resected lymph node biopsy was performed. The pathologic findings suggested lung adenocarcinoma, and the gene detection results indicated NM-005228:exon19:c.2235–2249del:p. GLu746-Ala750del (15.31%), NM-005228:exon20:c. G2356A: p. V786M (1.67%). The patient received the icotinib hydrochloride molecular targeted therapy. Outcomes After two months of treatment, pulmonary nodules were basically absent on chest CT scan re-examination. After nine months of treatment, no obvious abnormalities in the thoracic vertebral bone were found on 99mTc-MDP bone scan and CT scan re-examination. No obvious structural abnormalities, such as enlarged lymph nodes, could be found by ultrasound re-examination, and the patient remained alive without recurrence at the five-year follow-up. Conclusion This case report may provide a clue for the future development of molecular targeted therapy for lung cancer. It will allow surgeons to collaborate with oncologists and raise awareness of the benefit of the multidisciplinary approach to the diagnosis and treatment of cancer. Moreover, our results will help patients to fully understand the effect of nonsurgical treatments and improve confidence in the diagnosis and treatment of advanced lung cancer.

Interaction between SIRT1 and non-coding RNAs in different disorders

“…A number of therapeutic agents such as anthocyanins, ginsenoside-R3, dexmedetomidine hydrochloride, berberine, sorafenib, 17β-Estradiol, phenylpyridinium, tetrahydroxy stilbene glycoside, cisplatin, resveratrol, sulforaphane and liraglutide have been found to affect expression of non-coding RNAs/SIRT1 axes ( Table 4 ). For instance, experiments in animal model of asthma have shown that anthocyanins suppresses inflammatory responses in airways through decreasing activity of NF-κB pathway via the miR-138-5p/SIRT1 axis ( Liu Y. et al, 2022 ). Moreover, ginsenoside Rg3 can alleviate sepsis-related hepatic injury through modulation of TUG1/miR-200c-3p/SIRT1 axis ( Wu P. et al, 2021 ).…”

The safety and efficacy of the fissure-first approach in lung segmentectomy for patients with incomplete fissures

“…), additional small lung nodules have been subjected to pathological or genetic molecular diagnosis ( 4 , 5 ). In addition, the TNM staging of lung cancer has been optimized in multiple ways ( 6 , 7 ). So, interest in thoracic surgery for sublobar resection for early-stage lung cancer has increased again.…”